Drug Profile
Alpha D modulator
Latest Information Update: 15 May 2001
Price :
$50
*
At a glance
- Originator ICOS Corporation
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics
- Mechanism of Action ITGAD protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Inflammatory bowel diseases; Respiratory tract disorders; Rheumatoid arthritis
Most Recent Events
- 15 May 2001 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)
- 15 May 2001 Discontinued-Preclinical for Inflammatory bowel disease in USA (Unknown route)
- 15 May 2001 Discontinued-Preclinical for Respiratory tract disorders in USA (Unknown route)